DK2744515T3 - Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep - Google Patents
Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep Download PDFInfo
- Publication number
- DK2744515T3 DK2744515T3 DK12747923.6T DK12747923T DK2744515T3 DK 2744515 T3 DK2744515 T3 DK 2744515T3 DK 12747923 T DK12747923 T DK 12747923T DK 2744515 T3 DK2744515 T3 DK 2744515T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- combination therapy
- nitrogen mustard
- mustard
- nitrogen
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 title 1
- 229960004961 mechlorethamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| EP11177658 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US201261654097P | 2012-06-01 | 2012-06-01 | |
| PCT/EP2012/065906 WO2013024097A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2744515T3 true DK2744515T3 (da) | 2022-03-28 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12747923.6T DK2744515T3 (da) | 2011-08-16 | 2012-08-14 | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140255427A1 (enExample) |
| EP (2) | EP2744515B1 (enExample) |
| JP (1) | JP6184952B2 (enExample) |
| KR (3) | KR20200058583A (enExample) |
| CN (1) | CN103732252B (enExample) |
| AU (1) | AU2012296907B2 (enExample) |
| BR (1) | BR112013033919B1 (enExample) |
| CA (2) | CA3137321A1 (enExample) |
| CY (1) | CY1125122T1 (enExample) |
| DK (1) | DK2744515T3 (enExample) |
| ES (1) | ES2909722T3 (enExample) |
| HR (1) | HRP20220228T1 (enExample) |
| HU (1) | HUE058350T2 (enExample) |
| IL (1) | IL230293B (enExample) |
| LT (1) | LT2744515T (enExample) |
| MX (1) | MX354479B (enExample) |
| PL (1) | PL2744515T3 (enExample) |
| PT (1) | PT2744515T (enExample) |
| RS (1) | RS63238B1 (enExample) |
| RU (1) | RU2625222C2 (enExample) |
| SG (1) | SG10201606785UA (enExample) |
| SI (1) | SI2744515T1 (enExample) |
| SM (1) | SMT202200159T1 (enExample) |
| WO (1) | WO2013024097A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106794231A (zh) * | 2014-06-16 | 2017-05-31 | 赞科股份有限公司 | 用于慢性淋巴细胞性白血病（cll）的治疗 |
| HUE046328T2 (hu) * | 2015-05-26 | 2020-03-30 | Morphosys Ag | CD19 elleni ellenanyag és Bruton-féle tirozin-kináz gátlójának kombinációja és a kombináció alkalmazásai |
| AU2016311136B2 (en) * | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| PT3916392T (pt) * | 2016-05-30 | 2024-06-04 | Incyte Corp | Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes |
| LT3532098T (lt) * | 2016-10-28 | 2021-06-25 | Morphosys Ag | Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| WO2018220040A1 (en) | 2017-05-31 | 2018-12-06 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR20240131370A (ko) * | 2021-12-22 | 2024-08-30 | 인사이트 코포레이션 | 항-cd19 항체 요법을 위한 치료 패러다임 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| JP4169478B2 (ja) * | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| KR20020027311A (ko) * | 1999-05-07 | 2002-04-13 | 제넨테크, 인크. | Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료 |
| JP2004508420A (ja) | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| AU2005317047A1 (en) | 2004-11-05 | 2006-06-22 | Cephalon, Inc. | Cancer treatments |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| PT1966245E (pt) * | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| RS53263B (sr) * | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| LT2176298T (lt) | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| EA201170940A1 (ru) * | 2009-01-16 | 2012-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела |
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US20120128586A1 (en) | 2009-06-24 | 2012-05-24 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| KR20120054069A (ko) * | 2009-08-14 | 2012-05-29 | 로슈 글리카트 아게 | 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법 |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| JP2013510180A (ja) * | 2009-11-06 | 2013-03-21 | インフィニティ ファーマスーティカルズ、インク． | ヘッジホッグ経路阻害剤の経口製剤 |
-
2012
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko not_active Withdrawn
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 SM SM20220159T patent/SMT202200159T1/it unknown
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en not_active Ceased
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Ceased
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active Active
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100289T patent/CY1125122T1/el unknown
-
2024
- 2024-01-12 US US18/411,350 patent/US20240366756A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2744515T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep | |
| CY2021036I2 (el) | Αντισωματα anti-angptl3 και χρησεις αυτων | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| DK2744826T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en purin-analog | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| DK3502129T3 (da) | Konjugat omfattende oxyntomodulin og et immunoglobulinfragment og anvendelse deraf | |
| DK2683406T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| DK2917790T3 (da) | Horologe med opbevaret og interchangeable face | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| DK2776469T3 (da) | Antistofmolekyler med specificitet for human ox40 | |
| DK3045187T3 (da) | Injektor og fremgangsmåde til samling | |
| BR112014002219A2 (pt) | conjugados anticorpo p97 e métodos de sua utilização | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| DK2839860T3 (da) | Pyrrolobenzodiazepiner og konjugater deraf | |
| DK2914633T3 (da) | Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder | |
| DK3339323T3 (da) | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf | |
| DK2950535T3 (da) | Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand | |
| BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados |